136563-59-2

Upstream product

• 56441-54-4 4-ethoxycarbonylphenoxy-(4'-chlorophenyl)-methane 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 120-47-8 Ethyl 4-hydroxybenzoate 
• 62290-46-4 methyl 4-((4-chlorobenzyl)oxy)benzoate 
• 104-83-6 1-Chloro-4-(chloromethyl)benzene 

Downstream Products

• 1207742-97-9 C₂₂H₁₅Cl₂N₃O₃ 
• 136563-60-5 C₁₅H₁₁ClN₂O₃ 
• 1630012-71-3 C₁₉H₂₂ClN₃O₃ 
• 1630013-19-2 4-butyl-5-(4-(4-chlorobenzyloxy)phenyl)-2H-1,2,4-triazole-3(4H)-one 
• 1419965-88-0 3-{4'-(4''-chlorobenzyloxy)-phenyl}-4-amino-5-hydrazino-1,2,4-triazole 
• 1419968-45-8 3-[{4'-(4''-chlorobenzyloxy)-phenyl}-5-mercapto-1,2,4-triazol-4-yl]iminoisatin 
• 1419968-15-2 6-phenyl-5,6-dihydro-3-{4'-(4''-chlorobenzyloxy)-phenyl}-1,2,4-triazolo[3,4-b][1,3,4]thiadiazole 
• 1419967-86-4 3-{4'-(4''-chlorobenzyloxy)-phenyl}-7H-1,2,4-triazolo[3,4-b][1,3,4]thiadiazine-6(5H)-one 
• 1419967-58-0 3-{4'-(4''-chlorobenzyloxy)-phenyl}-1,2,4-triazolo[3,4-b][1,3,4]thiadiazole 
• 1419967-29-5 3-{4'-(4''-chlorobenzyloxy)-phenyl}-6-aminophenyl-5H-1,2,4-triazolo[3,4-b][1,3,4]thiadiazole 
• 1419967-01-3 6-phenyl-3-{4'-(4''-chlorobenzyloxy)-phenyl}-7H-1,2,4-triazolo[3,4-b][1,3,4]thiadiazine 
• 1419966-73-6 3-{4'-(4''-chlorobenzyloxy)-phenyl}-6,7-diphenyl-5H-1,2,4-triazolo[3,4-b][1,3,4]thiadiazine 
• 1419966-44-1 3-{4'-(4''-chlorobenzyloxy)-phenyl}-6-phenyl-1,2,4-triazolo[3,4-b][1,3,4]thiadiazole 
• 1419966-17-8 3-{4'-(4''-chlorobenzyloxy)-phenyl}-1,2,4-triazolo[3,4-b][1,3,4]thiadiazole-6(5H)-thione 

Relevant academic research and scientific papers

Synthesis and antifungal activity of 1-aminomethyl-3-{4- (chlorobenzyloxy) benzoylhydrazono}-4, 5/5, 6-dichloroindolin-2- ones

3-{4-(Chlorobenzyloxy) benzoylhydrazono}-4,5/5,6-dichloroindolin-2-ones 1a,b-5a,b, were synthesized by the condensation of 4-(chlorobenzyloxy) benzoylhydrazines and 4, 5/5, 6-dichloroindolin-2,3-diones. Compounds 1a,b-5a,b when subjected to Mannich reaction with secondary heterocyclic amines in the presence of formaldehyde, furnished 1-aminomethyl-3-{4-(chlorobenzyloxy) benzoylhydrazono}-4, 5/5, 6-dichloroindolin-2- ones 6a,b-20a,b. The structures of the compounds have been established by means of spectral (IR and 1H NMR) and elemental analysis. The compounds have been screened for their antifungal potential against human pathogenic fungi.

Synthesis and anticonvulsant activity evaluation of 4-butyl-5-(4- alkoxyphenyl)-2H-1,2,4-triazole-3(4H)-ones

A series of 4-butyl-5-(4-alkoxyphenyl)-2H-1,2,4-triazole-3(4H)-ones (6a-6u) was designed and synthesized. The anticonvulsant effects and neurotoxicity of the compounds were evaluated with maximal electroshock test and rotarod test. Among the synthetic compounds, 4-butyl-5-(4-(2-fluorinebenzyl)phenyl)-2H-1,2,4- triazole-3 (4H)-one (6k) was the most potent with ED50 value of 27.4 mg/kg and protective index (PI = TD50/ED50) value of 12.0. Besides the anti-MES efficacy, the potency of compound 6k against seizures induced by pentylenetetrazole (PTZ), 3-mercaptopropionic acid (3-MP), and bicuculline (BIC) was also established, which suggested that the mechanisms of action including enhancing of GABAergic activity might be involved in its anticonvulsant activity.

Synthesis and antimicrobial potential of Mannich bases of 4-chloro-3-{4-(chlorobenzyloxy)-benzoylhydrazono}-indolin-2-ones

4-Chloro-3-{4-(chlorobenzyloxy)-benzoylhydrazono}-indolin-2-ones (1-4) were synthesised by the condensation of 4-(chlorobenzyloxy)-benzoylhydrazines and 4-chloroisatin. On being subjected to aminomethylation in the presence of formaldehyde and heterocyclic secondary amines, indolinones 1-4, furnished aminomethylated indolinones (Mannich bases) 5-20. The structures of the compounds have been established by means of elemental analysis and spectral data (IR, PMR and Mass). The compounds have been screened for their antimicrobial potential against human pathogenic bacteria and fungi.

5-[4-(Benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives and related analogues: New reversible, highly potent, and selective monoamine oxidase type B inhibitors

Thirty-three new 5-[4-(benzyloxy)phenyl]-1,3,4-oxadiazol-2(3H)-one derivatives including related analogues, designed as inhibitors of monoamine oxidase type B (MAO B), were synthesized and investigated both in vitro and ex vivo for their abilities to inhibit selectively rat brain MAO B over MAO A. Three inhibitors were found to act as reversible, highly potent, and selective MAO B inhibitors, namely the nitrile derivative 5-[4- (benzyloxy)phenyl]-3-(2-cyanoethyl)-1,3,4-oxadiazol-2(3H)-one (12a) and two closely related homologues, the corresponding oxadiazolethione 13a and the alcohol 14b. Their IC50(MAO B) values are in the low nanomolar range of 1.4-4.6 nM and their selectivities, estimated by the ratio of IC50 values (A/B), are from 3200 to >71 400. Compound 12a exhibited the highest activity against MAO B. Its IC50 was evaluated to be 1.4 nM with a quasitotal selectivity (>71 400) toward this enzyme. In ex vivo studies, 12a showed a reversible and short duration of action. MAO B was markedly inhibited with the oral dose of 1 mg/kg without any alteration of MAO A, and the inhibition almost did not exceed 24 h. Its ED50 (1 h after oral administration) was evaluated to be 0.56 mg (1.7 μmol)/kg. Remarkably, MAO A was not affected at doses as high as 1500 mg/kg, po. In addition, no apparent toxicity or behavioral anomaly was observed during the treatment even at the maximum administrated dose. SAR studies emphasize the existence of three binding sites to the enzyme with a special importance of the terminal phenyl. Analysis of the inhibition kinetics indicated that 12a acts in a two-step mechanism as a competitive, slow, and tight-binding inhibitor of MAO B with a K(i) value of 0.22 μM and an overall K(i)* value at equilibrium of 0.7 nM.